NewG Lab Completes Name Change to 'NewG Lab Pharma'

[Asia Economy Reporter Hyunseok Yoo] NewG Lab announced on the 14th that it has completed its name change to ‘NewG Lab Pharma.’ Last month, NewG Lab stated at its regular shareholders' meeting that it would focus on the bio business as its core business through the name change.

NewG Lab Pharma has expanded its new drug development business starting in 2019 with Dr. Younghee Ko, a Korean-American scientist and successor to the anticancer theory of Dr. Otto Warburg from Germany, by beginning the commercialization development of the next-generation anticancer agent KAT (Ko Anticancer Technology).

Dr. Ko is the CEO of NewG Lab Pharma's U.S. branch, and her mentor, Peter Pedersen (former professor at Johns Hopkins University School of Medicine), serves as a scientific advisor. Currently, Dr. Ko is directing the entire preclinical and clinical process as the lead developer.

KAT, being developed by NewG Lab Pharma, recently applied for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA) targeting liver cancer and is preparing for full-scale clinical trials. Besides KAT, NewG Lab Pharma's representative pipelines include the non-small cell lung cancer treatment ‘Taletrektinib,’ the COVID-19 treatment ‘Nafamostat,’ and the oral COVID-19 treatment ‘Nafamostat Tablets.’

Recently, by acquiring ‘Arije Yak,’ which has Korea Good Manufacturing Practice (KGMP) facilities, and ‘Hanwool TL,’ a bio cold chain specialist company, NewG Lab Pharma plans to complete the pharmaceutical value chain from new drug development, production, sales, to delivery, establishing itself as a comprehensive pharmaceutical company and focusing on the pharmaceutical and bio business.